UT M.D. Anderson Cancer Center

描述（由申请人提供）：大约1000万美国人是生活在他们社区的癌症幸存者，80%的成人癌症治疗是在社区肿瘤学环境中提供的。为了实施临床试验，以适当的速度在癌症医学方面取得进展，并解决人口老龄化的重要需求，临床研究基础设施必须扩展到社区肿瘤环境中。我们的假设是，通过我们的研究基地，丰富癌症控制护理的临床试验，特别是在症状预防、症状管理、中西医结合、癌症预防、癌症控制和癌症治疗领域，可以通过最先进的医学在他们的社区提供给患者；随后，重要的癌症治疗相关信息和方法可以从社区转移回安德森癌症中心，以加强我们的研究项目和我们对癌症治疗的理解。我们的计划是完成现有的癌症治疗试验，不再进行进一步的治疗试验。我们将开发一个扩展的、重点的癌症控制研究项目，以响应我们的社区肿瘤学家和癌症医学领域的当前需求，癌症幸存者数量的增加以及为这一人群开发研究驱动模式的相关挑战，以及md安德森研究团队不断发展的优势。本建议的具体目标是：目标1。开展癌症防治领域的干预性临床试验，提高癌症患者的健康水平；子目标1a：在姑息治疗和康复领域开展和开展干预性临床试验；子目标1b：在支持肿瘤学领域开展和开展介入临床试验；子目标1c：开发和开展利用中西医结合领域的干预措施的干预试验（有时称为补充和替代医学）；分目标1d：开展和开展旨在改善癌症幸存者健康的干预性试验；子目标1e：利用症状评估和测量的最佳实践，并通过开展包括患者报告的结果测量在内的介入性临床试验，扩大这些领域的知识库；子目标1f：将新的贝叶斯方法纳入临床试验的设计和分析，包括使用患者报告的结果。目标2。交换医疗信息、科学技术和。通过协作开发实用的、创新的癌症控制试验，在我们的学术癌症中心教员和研究员、其他学术中心和社区肿瘤站点之间建立最佳实践标准。我们的研究基地致力于指导我们的研究项目进行临床试验，以满足我们的CCOP成员的兴趣、技能和实践环境，同时履行m.d. Anderson和NCI的使命，消除因癌症及其治疗引起的痛苦。

DESCRIPTION (provided by applicant): Approximately 10 million Americans are cancer survivors living in their communities, and 80% of adult cancer care is delivered in the community oncology setting. To implement clinical trials, make progress at an appropriate pace in cancer medicine, and address the vital needs of an aging population, the clinical research infrastructure must extend into the community oncology setting. Our hypothesis is that enriched clinical trials in cancer control care, especially in the areas of symptom prevention, symptom management, integrative medicine, cancer prevention, cancer control, and cancer treatment can be delivered to patients via state-of-the art medicine in their communities through our Research" Base; and subsequently, important cancer care-related information and approaches can be transferred back from the community to M. D. Anderson Cancer Center to enhance our research programs and our understanding of cancer care. Our plan is to complete our existing cancer treatment trials, and to develop no further treatment trials. We will develop an expanded, focused program of cancer control research in response to the current needs of our community oncologists and the field of cancer medicine, the increased number of cancer survivors and the associated challenges in developing research-driven models of care for this population, and the evolving strengths of the M. D. Anderson research faculty. The specific aims of this proposal are: Aim 1.To conduct interventional clinical trials in the realm of cancer control to enhance the health of patients affected by cancer; Sub-aim 1a: To develop and conduct interventional clinical trials in the realm of palliative care and rehabilitation; Sub-aim 1b: To develop and conduct interventional clinical trials in the realm of supportive oncology; Sub-aim 1c: To develop and conduct interventional trials that utilize interventions in the realm of integrative medicine (sometimes called complementary and alternative medicine); Sub-aim 1d: To develop and conduct interventional trials directed at improving the health of cancer survivors; Sub-aim 1e: To draw upon best practices in symptom assessment and measurement, and to expand the knowledge base in these realms through the conduct of interventional clinical trials that include patient-reported outcome measures; Sub-aim 1f: To incorporate novel Bayesian approaches to the design and analysis of clinical trials that include use of patient- reported outcomes. Aim 2. To exchange medical information, scientific technology, and. best practice standards among our academic cancer center faculty and fellows, other academic centers, and community oncology sites through collaborative development of practical, innovative cancer control trials. Our Research Base is committed to directing our research program toward conducting clinical trials to meet our CCOP members' interests, skills, and practice settings while fulfilling the mission of M. D. Anderson and the NCI to eliminate suffering attributable to cancer and its treatments.